Search results
Results from the WOW.Com Content Network
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]
Propranolol may cause harmful effects for the baby if taken during pregnancy; [7] however, its use during breastfeeding is generally considered to be safe. [8] It is a non-selective beta blocker which works by blocking β-adrenergic receptors. [2] Propranolol was patented in 1962 and approved for medical use in 1964. [9]
Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. [76] Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects ...
It is a beta blocker, specifically a selective β 1 receptor blocker, and is taken by mouth or is given intravenously. [4] Common side effects include trouble sleeping, feeling tired, feeling faint, and abdominal discomfort. [4] Large doses may cause serious toxicity. [5] [6] Risk in pregnancy has not been ruled out.
Dichloroisoprenaline (DCI), also known as dichloroisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β 1 -adrenergic and β 2 -adrenergic receptors . DCI has low potency and acts as a partial agonist / antagonist at these receptors .
Bisoprolol, sold under the brand name Zebeta among others, is a beta blocker which is selective for the beta-1 receptor [7] and used for cardiovascular diseases, [7] including tachyarrhythmias, high blood pressure, angina, and heart failure. [7] [8] It is taken by mouth. [7]
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Labetalol is often classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier and blood–placenta barrier. [ 17 ] [ 29 ] [ 30 ] This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects. [ 17 ]